Trials / Recruiting
RecruitingNCT07265622
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of 7MW4911 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 7MW4911 | 7MW4911 for IV infusion of various dose strengths administered |
Timeline
- Start date
- 2025-11-12
- Primary completion
- 2027-07-01
- Completion
- 2028-12-01
- First posted
- 2025-12-05
- Last updated
- 2025-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07265622. Inclusion in this directory is not an endorsement.